ストックスクリーナーアプリを入手
3.21
3.55%
0.11
プレマーケット:
3.15
-0.06
-1.87%
前日終値:
$3.10
開ける：
$3.11
24時間の取引高:
1.33M
Relative Volume:
0.86
時価総額：
$292.68M
収益：
$58.36M
当期純損益:
$-25.72M
株価収益率:
-8.8163
EPS:
-0.3641
ネットキャッシュフロー:
$-24.91M
1週間 パフォーマンス:
+5.25%
1か月 パフォーマンス:
-12.05%
6か月 パフォーマンス:
+0.31%
1年 パフォーマンス:
+31.56%
1日の値動き範囲:
$3.08
$3.22
1週間の範囲:
$3.04
$3.30
52週間の値動き範囲:
$2.24
$6.23
Aquestive Therapeutics Inc Stock (AQST) Company Profile
名前
Aquestive Therapeutics Inc
セクター
電話
908-941-1900
住所
30 TECHNOLOGY DRIVE, WARREN, NJ
AQST を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
3.21 | 292.68M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-05-10 | 開始されました | Leerink Partners | Outperform |
| 2024-04-11 | 開始されました | Piper Sandler | Overweight |
| 2024-03-28 | 開始されました | Raymond James | Outperform |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2019-04-22 | 開始されました | H.C. Wainwright | Buy |
| 2019-01-03 | 開始されました | Lake Street | Buy |
| 2018-08-20 | 開始されました | JMP Securities | Mkt Outperform |
| 2018-08-20 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Aquestive Therapeutics Inc (AQST) 最新ニュース
Head to Head Survey: Aquestive Therapeutics (NASDAQ:AQST) & Vistagen Therapeutics (NASDAQ:VTGN) - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Up 8.6% in December - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by Barclays PLC - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Anaphylaxis Market Poised for Significant Growth from 2023 to 2032, Reports DelveInsight | Aravax Pty Ltd, AstraZeneca, Aquestive Therapeutics - Barchart
Neuromuscular Disease Therapeutics Market to grow by USD 13.7 Billion from 2025-2029, driven by novel approvals, with AI impacting market trendsTechnavio - The Malaysian Reserve
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Neuromuscular Disease Therapeutics Market to Grow by USD 13.73 Billion from 2025-2029, Driven by Novel Approvals and AI-Driven Market TransformationTechnavio - The Malaysian Reserve
Aquestive Therapeutics Updates on Strategic Goals and Drug Progress - TipRanks
Aquestive Therapeutics Provides Business Update - citybiz
Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives - The Manila Times
Aquestive Therapeutics Targets 2026 Launch for Anaphylm as FDA Approves Pediatric Seizure Drug - StockTitan
Aquestive Therapeutics: Five Foci For 2025 (NASDAQ:AQST) - Seeking Alpha
Geode Capital Management LLC Has $8.31 Million Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Barclays PLC Buys 73,542 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
What Analysts Were Expecting After Aquestive Therapeutics Inc (NASDAQ: AQST) rose 4.21% - Stocks Register
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Sold by Stifel Financial Corp - Defense World
State Street Corp Has $7.45 Million Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
State Street Corp Purchases 512,682 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Stifel Financial Corp Sells 301,538 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive Therapeutics’ (AQST) “Buy” Rating Reiterated at HC Wainwright - Defense World
Aquestive receives FDA Orphan Drug Exclusivity for Libervant - MSN
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Rating of “Buy” from Analysts - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Aquestive shares reiterated at Buy by analyst as FDA grants ODE to Libervant - Investing.com Canada
Aquestive Therapeutics (NASDAQ:AQST) Receives "Buy" Rating from HC Wainwright - MarketBeat
Analysts Set Expectations for AQST FY2024 Earnings - Defense World
Wellington Management Group LLP Invests $922,000 in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive Therapeutics Gains FDA Orphan Drug Exclusivity for Pediatric Seizure Treatment - Yahoo Finance
Aquestive Therapeutics Receives U.S. FDA Orphan Drug - GlobeNewswire
Cantor Fitzgerald Forecasts AQST FY2024 Earnings - MarketBeat
The Price Is Right For Aquestive Therapeutics, Inc. (NASDAQ:AQST) Even After Diving 25% - Simply Wall St
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by BNP Paribas Financial Markets - Defense World
Cantor Fitzgerald Initiates Coverage on Aquestive Therapeutics (NASDAQ:AQST) - Defense World
Charles Schwab Investment Management Inc. Purchases 9,268 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics' SWOT analysis: stock poised for growth with innovative epinephrine delivery - Investing.com Canada
Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside - Yahoo Finance UK
Aquestive Therapeutics (NASDAQ:AQST) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat
Aquestive Therapeutics stock initiated at Overweight by Fitzgerald, eyes strong 2025 catalysts - Investing.com UK
Aquestive Therapeutics' (NASDAQ:AQST) investors will be pleased with their favorable 88% return over the last year - Yahoo Finance
Cantor Fitzgerald Initiates Coverage of Aquestive Therapeutics (AQST) with Overweight Recommendation - MSN
Aquestive Therapeutics (NASDAQ:AQST) shareholders have earned a 88% return over the last year - Simply Wall St
Aquestive Therapeutics' SWOT analysis: oral epinephrine stock poised for growth - Investing.com Nigeria
Aquestive Therapeutics' SWOT analysis: oral epinephrine stock poised for growth By Investing.com - Investing.com South Africa
Oral Thin Films Market Growth in Future Scope 2024-2031 | - openPR
Verition Fund Management LLC Takes $995,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive Therapeutics confirms FDA nod for Anaphylm trial By Investing.com - Investing.com Canada
Aquestive Therapeutics confirms FDA nod for Anaphylm trial - Investing.com
Aquestive Therapeutics Gains FDA Support for Anaphylm - TipRanks
Aquestive Therapeutics Inc (AQST) 財務データ
収益
当期純利益
現金流量
EPS
2.14%
大文字化:
|
ボリューム (24 時間):